GLP-1s aren’t just for skinny. We know they shrink bellies. Ozempic. Wegovy. Mounjaro. They’ve ruled the headlines, but now the narrative is shifting. They might fix what weight loss alone can’t. Specifically: inflammation. And tissue damage.
A study in Cell Metabolism dropped this insight. Semaglutide helps osteoarthritis. Not because you weigh less. But because the drug itself quiets the pain machinery. It stops cartilage destruction. Slows osteophyte growth. Lowers pain sensitivity. Weight loss? That’s a bonus. An additive effect. Both mechanisms work. One mechanical. One molecular.
Think about the scale of it. 530 million people suffer from osteoarthritis globally. Most cases are tied to obesity, yes. Fat puts pressure on joints. It causes metabolic syndrome. That slows healing. Fuels chronic fire in the tissues. Standard care is brutal. NSAIDs. Steroid injections. Pills that mask pain while the joint crumbles. Or you lose weight. Exercise more. The boring, hard, sustainable way.
This drug offers a dual path. Shrink the load. Extinguish the inflammation. Potent? Absolutely.
Semaglutide alleviates inflammation and tissue damage independent of weight loss
Access? Don’t expect easy answers. The price tag is a wall. Hundreds to thousands a month. Out of reach for most.
But things are moving. Slowly. Policy makers are pushing. Insurers are blinking. The CMS launched the Medicare GLP-1 Bridge. It’s a demo. Eligible Part D beneficiaries get the drugs. Dates matter: July 2026 to December 2027. Just two and a half years.
What comes next? The BALANCE model. Better Approaches to Lifestyle and Nutrition. A permanent shift? Maybe. It aims to stitch these drugs into the standard package.
We’ll see. The science looks good. The politics? Always messy. Will insurance pay? Will the lines get shorter?
Not yet.
